Dedicated to saving the lives of people diagnosed with Idiopathic Pulmonary Fibrosis, and other Fibrotic Diseases.
Phelix Therapeutics, LLC is dedicated to saving the lives of people diagnosed with Idiopathic Pulmonary Fibrosis, and other Fibrotic Diseases, by developing innovative treatments for these fatal conditions.Phelix Therapeutics continues to advance and commercialize the Calpain Inhibitor research and development work of Dr. Doron Greenbaum. The unique biological approach of Phelix Therapeutics relies on the insight that the connected processes of cellular injury/death and fibrosis can both be treated by inhibition of a single therapeutic target.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Jan 31, 2018 | Grant | $201.66K | 1 | National Institutes of Health | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
National Institutes of Health | Yes | Grant |